Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Takafumi Mie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7561-5558; OpenAlex author ID A5024647452. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2020: 3 papers · 2021: 8 papers · 2022: 8 papers · 2023: 6 papers · 2024: 2 papers · 2025: 9 papers · 2026: 5 papers

Papers 41

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  2. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  3. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  4. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. First author DOI 10.1159/000550483↗
  5. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  6. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  7. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1007/s10147-025-02796-0↗
  8. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  9. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  10. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  11. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  12. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  13. ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
  14. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  15. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Co-author DOI 10.1002/deo2.360↗
  16. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  17. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  18. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  19. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  20. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  21. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  22. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  23. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  24. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  25. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  26. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  27. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  28. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  29. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  30. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  31. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  32. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  33. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  34. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  35. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  36. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  37. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  38. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  39. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  40. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Co-author DOI 10.1055/a-1244-1989↗
  41. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masato Ozaka · 40 shared papers, 2020–2026 · strength 6.91
  2. Naoki Sasahira · 39 shared papers, 2020–2026 · strength 6.73
  3. Tsuyoshi Takeda · 34 shared papers, 2020–2026 · strength 5.81
  4. Takashi Sasaki · 34 shared papers, 2020–2026 · strength 5.62
  5. Takaaki Furukawa · 33 shared papers, 2020–2026 · strength 5.60
  6. Takeshi Okamoto · 25 shared papers, 2021–2026 · strength 4.71
  7. Akiyoshi Kasuga · 26 shared papers, 2020–2025 · strength 3.79
  8. Masato Matsuyama · 22 shared papers, 2020–2023 · strength 3.00
  9. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  10. Yosuke Inoue · 9 shared papers, 2020–2026 · strength 1.69
  11. Yu Takahashi · 9 shared papers, 2020–2026 · strength 1.41
  12. Atsushi Oba · 7 shared papers, 2022–2025 · strength 1.32
  13. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  14. Hiromichi Ito · 6 shared papers, 2022–2025 · strength 1.17
  15. Yukari Suzuki · 4 shared papers, 2025–2026 · strength 1.01
  16. Aya Maekawa · 4 shared papers, 2025 · strength 0.88
  17. Manabu Takamatsu · 4 shared papers, 2021–2026 · strength 0.68
  18. Yoshihiro Ono · 3 shared papers, 2025 · strength 0.68
  19. Kojiro Omiya · 3 shared papers, 2025 · strength 0.68
  20. Yoshihiro Ono · 4 shared papers, 2021–2025 · strength 0.60
  21. Jun Hamada · 2 shared papers, 2026 · strength 0.53
  22. Yu Takahashi · 2 shared papers, 2025 · strength 0.47
  23. Yuta Ushida · 3 shared papers, 2022 · strength 0.42
  24. Akio Saiura · 3 shared papers, 2020–2022 · strength 0.38
  25. Reo Maruyama · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.